Your browser doesn't support javascript.
loading
Post-Authorization Safety Studies of Acute Liver Injury and Severe Complications of Urinary Tract Infection in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.
Danysh, Heather E; Johannes, Catherine B; Beachler, Daniel C; Layton, J Bradley; Ziemiecki, Ryan; Arana, Alejandro; Dinh, Jade; Li, Ling; Calingaert, Brian; Pladevall-Vila, Manel; Hunt, Phillip R; Chen, Hungta; Karlsson, Cecilia; Johnsson, Kristina; Gilsenan, Alicia.
Afiliación
  • Danysh HE; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA, 02452-8413, USA. hdanysh@rti.org.
  • Johannes CB; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA, 02452-8413, USA.
  • Beachler DC; Department of Safety and Epidemiology, HealthCore, Inc., Wilmington, DE, USA.
  • Layton JB; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Ziemiecki R; Department of Biostatistics, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Arana A; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
  • Dinh J; Department of Research Operations, HealthCore, Inc., Wilmington, DE, USA.
  • Li L; Department of Safety and Epidemiology, HealthCore, Inc., Wilmington, DE, USA.
  • Calingaert B; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Pladevall-Vila M; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
  • Hunt PR; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA.
  • Chen H; BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD, USA.
  • Karlsson C; BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD, USA.
  • Johnsson K; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Gilsenan A; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Drug Saf ; 46(2): 175-193, 2023 02.
Article en En | MEDLINE | ID: mdl-36583828
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Urinarias / Diabetes Mellitus Tipo 2 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones Urinarias / Diabetes Mellitus Tipo 2 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: Drug Saf Asunto de la revista: TERAPIA POR MEDICAMENTOS / TOXICOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda